Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with high morbidity and mortality rates and lacks an effective treatment. Here, we report the therapeutic effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on hypertension + ...
Main Authors: | Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu, Yafeng Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0914-1 |
Similar Items
-
cGMP-Dependent Protein Kinase Inhibitors in Health and Disease
by: Jens Schlossmann, et al.
Published: (2013-02-01) -
Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01) -
Studies On The Molecular Mechanism Of S-Tide Mediated Activation Of Pkg-Iα
by: Charles, Joseph William
Published: (2019) -
Cyclic GMP-Dependent Regulation of Vascular Tone and Blood Pressure Involves Cysteine-Rich LIM-Only Protein 4 (CRP4)
by: Natalie Längst, et al.
Published: (2021-09-01) -
ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)